|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
BD Diagnostics received FDA clearance to market for its BD ProbeTec Urine Preservative Transport (UPT) urine specimen processing system for use with molecular tests on the BD ProbeTec System. The BD ProbeTec UPT extends the time and temperature of urine specimen transport to the laboratory when testing is not immediately possible. bioMerieux and ExonHit extended their 2003 agreement for the development of a diagnostic test for breast cancer. The scope of the collaboration has now been enlarged to other types of cancers, including colon, prostate and lung cancers. The objective of the extended collaboration is to develop DNA microarrays to detect genetic cancer markers in blood or tumor samples. ExonHit grants bioMerieux an exclusive license to use its technology and methods in the field of blood diagnostics, gene profiling and the design of microarrays. Cepheid launched its Research Use Only (RUO) product for the identification of cells carrying the BCR/ABL chromosomal translocation for use on the GeneXpert System. The BCR/ABL product is part of a broader program directed at investigating its potential use for monitoring patients with Chronic Myelogenous Leukemia. Genzyme Corporation entered into a license agreement with the University of California at Los Angeles (UCLA) Jonsson Cancer Center to obtain exclusive, worldwide diagnostic rights to its discovery of gene mutations believed to be associated with drug resistance to Gleevec (imatinib mesylate), the current first-line therapy for patients with chronic myeloid leukemia (CML). Metabolon, Inc. was awarded a contract from the Centers for Disease Control and Prevention (CDC) to identify methylation-based disease biomarkers for multiple sclerosis. Millipore and Gen-Probe have formed an alliance to develop, manufacture and commercialize on an exclusive basis nucleic acid testing products for rapid microbiological and virus monitoring in the biotech and pharmaceutical industries. Nanogen, Inc. launched the NanoChip 400, an electronic microarray system, upon which homebrew molecular assays can be developed in clinical and research laboratories. The new multi-purpose system combines sample and reagent handling robotics with detection in an instrument half the size of the NanoChip 100. Rubicon Genomics, Inc. entered a collaboration with Abbott Labs to develop and commercialize its MethylPlex methylation detection technology for diagnosis and prognosis of cancer. Sigma-Aldrich introduced the Panorama Human Cancer Version 1 Protein Functional Microarray developed by Procognia Ltd, UK. Licensed exclusively to Sigma-Aldrich, the Cancer V1 protein microarray contains 130 correctly folded proteins that are implicated in mediating cancer. Third Wave Technologies Inc. chose Genzyme Genetics as its preferred laboratory partner to provide testing with the Invader UGT1A1 Molecular Assay for colorectal cancer patients in the North American market who are being considered for, or currently taking, the chemotherapy Camptosar (irinotecan). Genzyme will undertake a direct education program aimed at oncologists and pathologists throughout North America.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: November 2, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
